



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA

# Biblioteca di Scienze del Farmaco

## **Banche dati bibliografiche** **PubMed**

**12 dicembre 2023**




- **PubMed** è una delle più importanti banche dati bibliografiche a livello internazionale. E' una risorsa gratuita per la ricerca e il recupero di riferimenti bibliografici ad articoli scientifici e ad altri documenti di ambito **biomedico e biologico**. Include anche riferimenti alla letteratura scientifica delle scienze del comportamento, della chimica e della bioingegneria.
- E' composta principalmente dalla banca dati bibliografica **Medline**, da articoli provenienti da **PMC** (PubMed Central) e da una sezione **Bookshelf** nella quale si possono trovare libri o capitoli di libri e/o altri documenti ad accesso aperto.
- Non include il full-text degli articoli, ma fornisce il **link al full-text**, quando questo è disponibile a vario titolo, ad esempio se l'articolo è ad accesso aperto o se un determinato articolo è pubblicato in una rivista scientifica per la quale l'Università paga un abbonamento.
- E' stato sviluppato e viene gestito dal **NCBI** (National Center for Biotechnology Information), presso la **NLM** (National Library of Medicine). Entrambi fanno parte dei **NIH** (National Institutes of Health) degli Stati Uniti.



# I termini MeSH in PubMed

- **MeSH** è la sigla per **Medical Subject Headings**.
- I Subject Headings costituiscono un vocabolario specialistico (MeSH) curato dalla NLM (National Library of Medicine). All'interno del vocabolario i termini sono inseriti in relazione gerarchica. Nel MeSH sono inclusi anche sinonimi, quasi-sinonimi e termini alternativi.
- I Subject Headings sono parole o stringhe di parole che vengono attribuite agli articoli presenti in PubMed da un team di specialisti.
- Servono a facilitare il recupero degli articoli all'interno di PubMed, ma recuperano solo una parte degli articoli, quelli presenti nella sezione **Medline** di Pubmed.
- Gli articoli non corredati dai termini MeSH, inclusi i Medline più recenti, si recuperano con l'uso di parole chiave libere (linguaggio naturale).





NIH National Library of Medicine  
National Center for Biotechnology Information

Log in

PubMed.gov

alzheimer drugs Search

Advanced

PubMed® comprises more than 34 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites.

**Learn**  
About PubMed  
FAQs & User Guide

**Find**  
Advanced Search  
Clinical Queries

**Download**  
E-utilities API  
FTP

**Explore**  
MeSH Database  
Journals



Log in

  
alzheimer drugs  
anti-alzheimer drugs

Search

Citations may include links to full text content from Pubmed Central and publisher web sites.

Pagina dei  
risultati

NIH National Library of Medicine  
National Center for Biotechnology Information

Log in

PubMed®

alzheimer drugs

Search

Advanced Create alert Create RSS

User Guide

Filtro  
cronologico

Save

Email

Send to

Sort by: Most recent


Display options

MY NCBI FILTERS

17,424 results

Page 1 of 1,743

RESULTS BY YEAR



TEXT AVAILABILITY

Abstract

[Research progress on biomarkers and detection methods for **Alzheimer's disease diagnosis in vitro**].

Zhang YT, Zhang Z, Zhang YC, Xu X, Wang ZM, Shen T, An XH, Chang D.

Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Nov 6;57(11):1888-1894. doi:

10.3760/cma.j.cn112150-20230517-00385.

PMID: 38008582 Chinese.

**Alzheimer's disease** (AD) is a neurodegenerative **disease** with insidious onset, posing a serious threat to human physical and mental health. ...In vitro diagnostic biomarkers not only contribute to the early clinical diagnosis of AD but also aid in furth ...

Blood-brain barrier transporters: An overview of function, dysfunction in





alzheimer drugs

Search

Advanced Create alert Create RSS

User Guide

Save Email Send to

Sort by: Most recent

Display options

MY NCBI FILTERS

10,186 results

Page 1 of 1,019

RESULTS BY YEAR



[Research progress on biomarkers and detection methods for **Alzheimer's disease diagnosis *in vitro***].

Cite Zhang YT, Zhang Z, Zhang YC, Xu X, Wang ZM, Shen T, An XH, Chang D.

Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Nov 6;57(11):1888-1894. doi:

Share 10.3760/cma.j.cn112150-20230517-00385.

PMID: 38008582 Chinese.

**Alzheimer's disease** (AD) is a neurodegenerative **disease** with insidious onset, posing a serious threat to human physical and mental health. ...In vitro diagnostic biomarkers not only contribute to the early clinical diagnosis of AD but also aid in furth

Filtro  
cronologico  
applicato ai  
risultati





alzheimer drugs

Search

Advanced

Create alert

Create RSS

User Guide

Save

Email

Send to

Sort by:

Most recent

Display options

MY NCBI FILTERS

10,186 results

Page 1 of 1,019

RESULTS BY YEAR

Reset



[Research progress on biomarkers and detection methods for **Alzheimer's disease diagnosis in vitro**].

Cite Zhang YT, Zhang Z, Zhang YC, Xu X, Wang ZM, Shen T, An XH, Chang D.

Share Zhonghua Yu Fang Yi Xue Za Zhi. 2023 Nov 6;57(11):1888-1894. doi:

10.3760/cma.j.cn112150-20230517-00385.

PMID: 38008582 Chinese.

**Alzheimer's disease (AD)** is a neurodegenerative **disease** with insidious onset, posing a serious threat to human physical and mental health. ...In vitro diagnostic biomarkers not only contribute to the early clinical diagnosis of AD but also aid in furth ...

TEXT AVAILABILITY

Abstract

Blood-brain barrier transporters: An overview of function, dysfunction in **Alzheimer's disease** and strategies for treatment.

Microsoft Edge



Pagina della  
ricerca  
advanced

### PubMed Advanced Search Builder



User Guide

Add terms to the query box

All Fields

Enter a search term

ADD

Show Index

Query box

Enter / edit your search query here

Search

Storico delle  
ricerche  
eseguite

### History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#2	...	>	Search: <b>alzheimer drugs</b> Filters: <b>from 2014 - 2024</b> Sort by: <b>Most Recent</b>	10,186	05:38:06
#1	...	>	Search: <b>alzheimer drugs</b> Sort by: <b>Most Recent</b>	17,424	05:37:54

Showing 1 to 2 of 2 entries

### History and Search Details

Download

Search	Actions	Details	Query	Results
#2		>	Search: <b>alzheimer drugs</b> Filters: <b>from 2014 - 2024</b> Sort by: <b>Most Recent</b>	10,18
#1		▼	Search: <b>alzheimer drugs</b> Sort by: <b>Most Recent</b> ("alzeime s"[All Fields] OR "alzheimer disease"[MeSH Terms] OR ("alzheimer"[All Fields] AND "disease"[All Fields]) OR "alzheimer disease"[All Fields] OR "alzheimer"[All Fields] OR "alzheimers"[All Fields] OR "alzheimer s"[All Fields] OR "alzheimers s"[All Fields]) AND ("drug s"[All Fields] OR "pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR "drugs"[All Fields]) <b>Translations</b> <b>alzheimer:</b> "alzeime's"[All Fields] OR "alzheimer disease"[MeSH Terms] OR ("alzheimer"[All Fields] AND "disease"[All Fields]) OR "alzheimer disease"[All Fields] OR "alzheimer"[All Fields] OR "alzheimers"[All Fields] OR "alzheimer's"[All Fields] OR "alzheimers's"[All Fields] <b>drugs:</b> "drug's"[All Fields] OR "pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR "drugs"[All Fields]	

Showing 1 to 2 of 2 entries

PubMed amplifica la ricerca dei termini inserendo sinonimi e usando gli operatori booleani


MY NCBI FILTERS

3,606 results

Page 1 of 361

RESULTS BY YEAR

Reset



TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

ARTICLE ATTRIBUTE

- Associated data

ARTICLE TYPE

- Books and Documents
- Clinical Trial
- Meta-Analysis
- Randomized Controlled Trial
- Review
- Systematic Review

PUBLICATION DATE

Filters applied: Review, Systematic Review. [Clear all](#)

Blood-brain barrier transporters: An overview of function, dysfunction in **Alzheimer's disease** and strategies for treatment

Cite Chaves JCS, Dando SJ, White AR, Oikari LE.  
Biochim Biophys Acta Mol Basis Dis. 2023 Nov 24;166967. doi: 10.1016/j.bbabm.2023.166967.  
Share ahead of print.  
PMID: 38008230 Review.

Key players in BBB function are BBB transporters which are highly expressed in brain endothelial cells (BECs) and critical in mediating the exchange of nutrients and waste products. BBB transporters influence **drug** delivery into the brain by inhibiting or facilitating ...

Environmental Toxins and **Alzheimer's Disease**: a Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation.

Cite Dhapola R, Sharma P, Kumari S, Bhatti JS, HariKrishnaReddy D.  
Mol Neurobiol. 2023 Nov 25. doi: 10.1007/s12035-023-03805-x. Online ahead of print.  
Share PMID: 38006469 Review.

**Alzheimer's disease** is a leading cause of mortality worldwide. Inorganic and organic hazardous substances such as heavy metals, pesticides, agrochemicals, and air pollution are major environmental concerns. ...We emphasized upon the signaling pathways involve ...

Research Progress on Natural Plant Molecules in Regulating the Blood-Brain Barrier in **Alzheimer's Disease**.

Cite Wu W, Huang J, Han P, Zhang J, Wang Y, Jin F, Zhou Y.  
Molecules. 2023 Nov 16;28(22):7631. doi: 10.3390/molecules28227631.  
Share PMID: 38005352 [Free PMC article](#). Review.

**Alzheimer's disease** (AD) is a prevalent neurodegenerative disorder. ...Additionally, we analyze their specific mechanisms to offer novel insights for the development of safe and effective targeted **drugs** as well as guidance for experimental research and ...

Uso dei filtri

La review è un tipo di articolo in cui gli autori esaminano in modo critico, e possibilmente esaustivo, gli studi pubblicati su un determinato argomento.



# Ricerca advanced







PubM      [User Guide](#)

Sort by:

MY NCBI FILTERS

3,606 results

Page 1 of 361

RESULTS BY YEAR



TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

ARTICLE ATTRIBUTES

Filters applied: Review, Systematic Review. [Clear all](#)

- 1 **Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment.**  
Chaves JCS, Dando SJ, White AR, Oikari LE.  
Biochim Biophys Acta Mol Basis Dis. 2023 Nov 24;166967. doi: 10.1016/j.bbadis.2023.166967. Online ahead of print.  
PMID: 38008230 [Review](#).  
Key players in BBB function are BBB transporters which are highly expressed in brain endothelial cells (BECs) and critical in mediating the exchange of nutrients and waste products. BBB transporters can also influence **drug** delivery into the brain by inhibiting or facilitat ...
- 2 **Environmental Toxins and Alzheimer's Disease: a Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation.**



### PubMed Advanced Search Builder



Rimuovere  
i filtri

Filters applied: Review, Systematic Review. [Clear all](#)

Add terms to the query box

All Fields

Enter a search term

ADD

Show Index

Query box

Enter / edit your search query here

Search

### History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#4	...	>	Search: <b>alzheimer drugs</b> Filters: <b>Review, Systematic Review, from 2014 - 2024</b> Sort by: <b>Most Recent</b>	3,606	05:44:50
#3	...	>	Search: <b>alzheimer drugs</b> Filters: <b>Review, from 2014 - 2024</b> Sort by: <b>Most Recent</b>	3,481	05:44:43
#2	...	>	Search: <b>alzheimer drugs</b> Filters: <b>from 2014 - 2024</b> Sort by: <b>Most Recent</b>	10,186	05:44:27





Riutilizzare una query precedente e aggiungere altri termini alla ricerca

PubMed Advanced Search Builder



Add terms to the query box

All Fields

ADD

Show Index


Query box

Search

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#4	...	>	Search: <b>alzheimer drugs</b> Filters: <b>Review, Systematic Review, from 2014 - 2024</b> Sort by: <b>Most Recent</b>	3,606	05:44:50
#3	...	>	Search: <b>alzheimer drugs</b> Filters: <b>Review, from 2014 - 2024</b> Sort by: <b>Most Recent</b>	3,481	05:44:43
#2	...	>	Search: <b>alzheimer drugs</b> Filters: <b>from 2014 - 2024</b> Sort by: <b>Most Recent</b>	10,186	05:44:27
#1	...	>	Search: <b>alzheimer drugs</b> Sort by: <b>Most Recent</b>	17,424	05:37:54



Nuovo termine  
aggiunto

3

2

Query  
precedente

Search Builder

PubMed®  
User Guide

Add terms to the query box

All Fields efficacy [X] AND [v]

Query box

alzheimer drugs AND (2014:2024[pdat]) [X] Search [v]

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#4	...	>	Search: <b>alzheimer drugs</b> Filters: <b>Review, Systematic Review, from 2014 - 2024</b> Sort by: <b>Most Recent</b>	3,606	05:44:50
#3	...	>	Search: <b>alzheimer drugs</b> Filters: <b>Review, from 2014 - 2024</b> Sort by: <b>Most Recent</b>	3,481	05:44:43
#2	...	>	Search: <b>alzheimer drugs</b> Filters: <b>from 2014 - 2024</b> Sort by: <b>Most Recent</b>	10,186	05:44:27
#1	...	>	Search: <b>alzheimer drugs</b> Sort by: <b>Most Recent</b>	17,424	05:37:54

Showing 1 to 4 of 4 entries



### PubMed Advanced Search Builder



Add terms to the query box

All Fields

AND

Show Index

Query box

(alzheimer's drugs AND (2014:2024[pdat])) AND (efficacy)

4



5

(alzheimer's drugs AND (2014:2024[pdat])) AND (efficacy)



Search

[Advanced](#) [Create alert](#) [Create RSS](#)

[User Guide](#)

Save

Email

Send to

Sort by: Best match


Display options

MY NCBI FILTERS

1,370 results

Page 1 of 137

RESULTS BY YEAR



TEXT AVAILABILITY

- Abstract
- Free full text

[Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting \*\*drugs\*\* for \*\*Alzheimer's disease\*\* with potential for near term approval.](#)

Cite Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M.

Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.

Share PMID: 32787971 [Free PMC article.](#) [Review.](#)

The body of evidence suggesting a causative, initiating role of beta amyloid (Abeta) in the pathogenesis of **Alzheimer's disease** (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful **efficacy** in clinical trials. ...Only the high ...

[Neuroprotective Herbs for the Management of \*\*Alzheimer's Disease\*\*.](#)

Cite Gregory J, Vengalasetti YV, Bredesen DE, Rao RV.

Biomolecules. 2021 Apr 8;11(4):543. doi: 10.3390/biom11040543.

PMID: 33917842 [Free PMC article.](#) [Review.](#)



Back to Top

Mostra desktop

Modificare la  
visualizzazione  
dei risultati

Library of Medicine  
for Biotechnology Information

Log in

(alzheimer's drugs AND (2014:2024[pdat])) AND (efficacy)

Search

Advanced Create alert Create RSS

User Guide

Sort by: Best match

Display options ⚙

Best match

Most recent

Publication date


First author

Journal

MY NCBI FILTERS

1,370 results

RESULTS BY YEAR



TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

1 **Aducanumab, gantenerumab, BAN2401, and other anti-amyloid-beta monoclonal antibodies: a new wave of amyloid- $\beta$  targeting drugs for Alzheimer's disease** v...  
Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh...  
Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.  
PMID: 32787971 **Free PMC article.** Review.  
The body of evidence suggesting a causative, initiating role of beta amyloid (A $\beta$ ) in the pathogenesis of **Alzheimer's disease** (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful **efficacy** in clinical trials. ...Only the high ...

2 **Neuroprotective Herbs for the Management of Alzheimer's Disease.**  
Gregory J, Vengalasetti YV, Bredesen DE, Rao RV.  
Biomolecules. 2021 Apr 8;11(4):543. doi: 10.3390/biom11040543.  
PMID: 33917843 **Free PMC article.** Review.





I link al full text

(alzheimer's drugs AND (2014:2024[pdat])) AND (efficacy)

Search

User Guide

Save

Email

Send to

Display options ⚙

Review > Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.

## Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval

Martin Tolar<sup>1</sup>, Susan Abushakra<sup>2</sup>, John A Hey<sup>2</sup>, Anton Porsteinsson<sup>3</sup>, Marwan Sabbagh<sup>4</sup>

Affiliations + expand

PMID: 32787971 PMCID: PMC7424995 DOI: 10.1186/s13195-020-00663-w

Free PMC article

### FULL TEXT LINKS

Read free full text at BMC

FREE Full text PMC

### ACTIONS

Cite

Collections

NEXT RESULT  
2 of 1,370



Scaricare un  
articolo

Search in PMC

Advanced Search | User Guide

Journal List

As  
of  
Le

scientific literature. Inclusion in an NLM database does not imply endorsement  
of  
NLM or the National Institutes of Health.  
Le  
[Copyright Notice](#)

OTHER FORMATS

[PubReader](#) | [PDF \(412K\)](#)

ACTIONS

“ Cite

📖 Collections

SHARE



RESOURCES

Similar articles +

Cited by other articles +

Links to NCBI Databases +



[Alzheimers Res Ther.](#) 2020; 12: 95.

Published online 2020 Aug 12. doi: [10.1186/s13195-020-00663-w](https://doi.org/10.1186/s13195-020-00663-w)

PMCID: PMC7424995

PMID: [32787971](https://pubmed.ncbi.nlm.nih.gov/32787971/)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

[Martin Tolar](#)<sup>1</sup>, [Susan Abushakra](#)<sup>1</sup>, [John A. Hey](#)<sup>1</sup>, [Anton Porsteinsson](#)<sup>2</sup> and [Marwan Sabbagh](#)<sup>3</sup>

▶ [Author information](#) ▶ [Article notes](#) ▶ [Copyright and License information](#) [PMC Disclaimer](#)

Alzheimers Res Ther

Feedback







Tolar et al. *Alzheimer's Research & Therapy* (2020) 12:95  
<https://doi.org/10.1186/s13195-020-00663-w>

Alzheimer's  
Research & Therapy

REVIEW

Open Access

# Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval



Martin Tolar<sup>1\*</sup>, Susan Abushakra<sup>1</sup>, John A. Hey<sup>1</sup>, Anton Porsteinsson<sup>2</sup> and Marwan Sabbagh<sup>3</sup>

## Abstract

The body of evidence suggesting a causative, initiating role of beta amyloid (A $\beta$ ) in the pathogenesis of Alzheimer's disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful efficacy in clinical trials. We evaluated the unifying characteristics of anti-amyloid agents with positive clinical or biomarker effects in long-duration trials and analyzed how pharmacological characteristics determine their clinical product profiles. Four agents with the potential for near term approval fulfill these criteria: the injectable antibodies, aducanumab, gantenerumab, and BAN2401, and a small molecule oral agent, ALZ-801. Aducanumab and BAN2401 showed significant efficacy on both clinical and biomarker outcomes; gantenerumab showed significant biomarker effects, with no clinical efficacy reported to date; and ALZ-801 showed significant clinical effects in the high-risk population of patients homozygous for the  $\epsilon$ 4 allele of

Vodafone-65840315  
Accesso a Internet



### Similar articles

[Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.](#)

Tolar M, Hey J, Power A, Abushakra S.

Int J Mol Sci. 2021 Jun 14;22(12):6355. doi: 10.3390/ijms22126355.

PMID: 34198582 [Free PMC article.](#) [Review.](#)

[Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.](#)

Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M.

CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0.

PMID: 30076539 [Free PMC article.](#) [Clinical Trial.](#)

[The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis.](#)

Tolar M, Abushakra S, Sabbagh M.

Alzheimers Dement. 2020 Nov;16(11):1553-1560. doi: 10.1016/j.jalz.2019.09.075. Epub 2020 Jan 3.

PMID: 31706733 [Review.](#)

[Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.](#)

Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA.

CNS Drugs. 2017 Jun;31(6):495-509. doi: 10.1007/s40263-017-0434-z.

In PubMed si  
possono  
trovare link ad  
articoli simili a  
quello che si sta  
consultando



### Cited by

[Transferrin-Conjugated Melittin-Loaded L-Arginine-Coated Iron Oxide Nanoparticles for Mitigating Beta-Amyloid Pathology of the 5XFAD Mouse Brain.](#)

Choi M, Ryu J, Vu HD, Kim D, Youn YJ, Park MH, Huynh PT, Hwang GB, Youn SW, Jeong YH.

Int J Mol Sci. 2023 Oct 6;24(19):14954. doi: 10.3390/ijms241914954.

PMID: 37834402 [Free PMC article.](#)

[Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.](#)

Buccellato FR, D'Anca M, Tartaglia GM, Del Fabbro M, Scarpini E, Galimberti D.

Int J Mol Sci. 2023 Sep 9;24(18):13900. doi: 10.3390/ijms241813900.

PMID: 37762203 [Free PMC article.](#) [Review.](#)

[The emerging role of blood biomarkers in diagnosis and treatment of Alzheimer's disease.](#)

McGettigan S, Nolan Y, Ghosh S, O'Mahony D.

Eur Geriatr Med. 2023 Oct;14(5):913-917. doi: 10.1007/s41999-023-00847-1.

PMID: 37648817 No abstract available.

[Sulfur-bridging the gap: investigating the electrochemistry of novel copper chelating agents for Alzheimer's disease applications.](#)

Crnich E, Sanchez E, Havens MA, Kissel DS.

J Biol Inorg Chem. 2023 Oct;28(7):643-653. doi: 10.1007/s00775-023-02013-1. Epub 2023 Aug 18.

PMID: 37594567

In PubMed si  
possono  
trovare link ad  
articoli più  
recenti che  
citano quello  
che si sta  
consultando



# Ricerca con il MeSH



Log in

PubMed.gov

Search

Advanced

PubMed® comprises more than 34 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites.



**Learn**

About PubMed  
FAQs & User Guide  
Finding Full Text



**Find**

Advanced Search  
Clinical Queries  
Single Citation Matcher



**Download**

E-utilities API  
FTP  
Batch Citation Matcher



**Explore**

MeSH Database  
Journals







MeSH

MeSH

Limits Advanced

Search

Help



## MeSH

MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.

### Using MeSH

[Help](#)

[Tutorials](#)

### More Resources

[E-Utilities](#)

[NLM MeSH Homepage](#)

You are here: [NCBI](#) > [Literature](#) > [MeSH Database](#)

[Support Center](#)

FOLLOW NCBI

Search results

Items: 1 to 20 of 36

<< First < Prev Page 1 of 2 Next > Last >>

[Alzheimer Disease](#)

1. A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROFIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)  
Year introduced: 1998(1963)

[Alzheimer Vaccines](#)

2. Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.  
Year introduced: 2002

[Alzheimer disease, familial, type 3 \[Supplementary Concept\]](#)

3. Date introduced: August 25, 2010

[Alzheimer disease type 2 \[Supplementary Concept\]](#)

4. Date introduced: August 25, 2010

[Amyloid beta-Peptides](#)

5. Peptides generated from AMYLOID BETA-PEPTIDES PRECURSOR. An amyloid fibrillar form of these peptides is the major component of amyloid plaques found in individuals with Alzheimer's disease and in aged individuals with trisomy 21 (DOWN SYNDROME). The peptide is found predominantly in the nervous system, but there have been reports of its presence in non-neural

Nel MeSH i subject headings hanno un link con una spiegazione del termine o dei termini selezionati



**1**

MeSH MeSH Search Limits Advanced Help

### Alzheimer Disease

A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)  
Year introduced: 1998(1963)

PubMed search builder options  
[Subheadings:](#)

<input type="checkbox"/> analysis	<input type="checkbox"/> enzymology	<input type="checkbox"/> physiology
<input type="checkbox"/> anatomy and histology	<input type="checkbox"/> epidemiology	<input type="checkbox"/> physiopathology
<input type="checkbox"/> blood	<input type="checkbox"/> ethnology	<input type="checkbox"/> prevention and control
<input type="checkbox"/> cerebrospinal fluid	<input type="checkbox"/> etiology	<input type="checkbox"/> psychology
<input type="checkbox"/> chemically induced	<input type="checkbox"/> genetics	<input type="checkbox"/> radiotherapy
<input type="checkbox"/> classification	<input type="checkbox"/> history	<input type="checkbox"/> rehabilitation
<input type="checkbox"/> complications	<input type="checkbox"/> immunology	<input type="checkbox"/> statistics and numerical data
<input type="checkbox"/> congenital	<input type="checkbox"/> metabolism	<input type="checkbox"/> surgery
<input type="checkbox"/> diagnosis	<input type="checkbox"/> microbiology	<input type="checkbox"/> therapy
<input type="checkbox"/> diagnostic imaging	<input type="checkbox"/> mortality	<input type="checkbox"/> transmission
<input type="checkbox"/> diet therapy	<input type="checkbox"/> nursing	<input type="checkbox"/> urine
<input checked="" type="checkbox"/> drug therapy	<input type="checkbox"/> parasitology	
<input type="checkbox"/> economics	<input type="checkbox"/> pathology	
<input type="checkbox"/> embryology		

Restrict to MeSH Major Topic.  
 Do not include MeSH terms found below this term in the MeSH hierarchy.

Tree Number(s): C10.228.140.380.100, C10.874.945.249, F03.615.400.100  
MeSH Unique ID: D000544

**2**

PubMed Search Builder

"Alzheimer Disease/drug therapy"  
[Majr]

Add to search builder  
Search PubMed

Related information  
PubMed  
PubMed - Major  
Clinical Queries  
NLM MeSH Bro  
dbGaP Links  
MedGen

Alzheimer D  
alzheimer (36)

**I subheadings servono a limitare la ricerca a un determinato ambito.**



MeSH

MeSH efficacy

Search

Help

Full

Send to:

### Alzheimer Disease

A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROFIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Year introduced: 1998(1963)

PubMed search builder options

[Subheadings:](#)

- |  |  |  |
|--|--|--|
| <input type="checkbox"/> analysis                | <input type="checkbox"/> enzymology                      | <input type="checkbox"/> physiology                    |
| <input type="checkbox"/> anatomy and histology   | <input type="checkbox"/> epidemiology                    | <input type="checkbox"/> physiopathology               |
| <input type="checkbox"/> blood                   | <input type="checkbox"/> ethnology                       | <input type="checkbox"/> prevention and control        |
| <input type="checkbox"/> cerebrospinal fluid     | <input type="checkbox"/> etiology                        | <input type="checkbox"/> psychology                    |
| <input type="checkbox"/> chemically induced      | <input type="checkbox"/> genetics                        | <input type="checkbox"/> radiotherapy                  |
| <input type="checkbox"/> classification          | <input type="checkbox"/> history                         | <input type="checkbox"/> rehabilitation                |
| <input type="checkbox"/> complications           | <input type="checkbox"/> immunology                      | <input type="checkbox"/> statistics and numerical data |
| <input type="checkbox"/> congenital              | <input type="checkbox"/> metabolism                      | <input type="checkbox"/> surgery                       |
| <input type="checkbox"/> diagnosis               | <input type="checkbox"/> microbiology                    | <input type="checkbox"/> therapy                       |
| <input type="checkbox"/> diagnostic imaging      | <input type="checkbox"/> mortality                       | <input type="checkbox"/> transmission                  |
| <input type="checkbox"/> diet therapy            | <input type="checkbox"/> nursing                         | <input type="checkbox"/> urine                         |
| <input checked="" type="checkbox"/> drug therapy | <input type="checkbox"/> organization and administration | <input type="checkbox"/> veterinary                    |
| <input type="checkbox"/> economics               | <input type="checkbox"/> parasitology                    | <input type="checkbox"/> virology                      |
| <input type="checkbox"/> embryology              | <input type="checkbox"/> pathology                       |  |

Restrict to MeSH Major Topic.

Do not include MeSH terms found below this term in the MeSH hierarchy.

Tree Number(s): C10.228.140.380.100, C10.574.945.249, F03.615.400.100

MeSH Unique ID: D000544

#### PubMed Search Builder

"Alzheimer Disease/drug therapy"  
[Majr]

Add to search builder AND

Search PubMed

YouTube Tutorial

#### Related information

PubMed

PubMed - Major Topic

Clinical Queries

NLM MeSH Browser

dbGaP Links

MedGen

#### Recent Activity

Turn Off Clear

efficacy (0)

MeSH

Alzheimer Disease

MeSH

Concetti o entry terms vicini al termine efficacy.

National Library of Medicine  
National Center for Biotechnology Information

MeSH efficacy Search

Create alert Limits Advanced Help

Page 1 of 4

PubMed Search Builder  
"Alzheimer Disease/drug therapy" [Majr]  
Add to search builder Search PubMed

Find related data  
Database: Select Find items

Search details  
efficacy[All Fields] Search See more...

- [Efficacy](#)  
1. A cognitive mechanism based on expectations or beliefs about one's ability to perform actions necessary to produce a given effect. It is a theoretical component of behavior change in various therapeutic treatments. (APA, Thesaurus of Psychological Index Terms, 4)  
Year introduced: 1999
- [Vaccine Efficacy](#)  
2. A measurement of disease risk reduction among vaccinated compared to unvaccinated persons under ideal conditions such as in a clinical trial. Such disease reduction measured under typical field conditions is vaccine effectiveness. In contrast vaccine potency is measured in an assay to ensure proper dosing and storage of vaccines whereas vaccine immunogenicity measures its ability to induce an immune response in a vaccinated individual in observational studies.  
Year introduced: 2022
- [Treatment Outcome](#)  
3. Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the **efficacy**, effectiveness, safety, and practicability of these interventions in individual cases or series.  
Year introduced: 1992
- [Therapeutic Equivalency](#)  
4. The relative equivalency in the **efficacy** of different modes of treatment of a disease, most often used to compare the **efficacy** of different pharmaceuticals to treat a given disease.

MeSH

MeSH

efficacy

Search

Create alert Limits Advanced

Help

Summary 20 per page

### Search results

Items: 1 to 20 of 67 Selected: 1

<< First < Prev Page 1 of 4 Next > Last >>

#### Self Efficacy

1. Cognitive mechanism based on expectations or beliefs about one's ability to perform actions necessary to produce a given effect. It is also a theoretical component of behavior change in various therapeutic treatments. (APA, Thesaurus of Psychological Index Terms, 1994)  
Year introduced: 1999

#### Vaccine Efficacy

2. A measurement of disease risk reduction among vaccinated compared to unvaccinated persons under ideal conditions such as in a clinical trial. Such disease reduction measured under typical field conditions is vaccine effectiveness. In contrast vaccine potency is measured in an assay to ensure proper dosing and storage of vaccines whereas vaccine immunogenicity measures its ability to induce an immune response in a vaccinated individual in observational studies.  
Year introduced: 2022

#### Treatment Outcome

3. Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the **efficacy**, effectiveness, safety, and practicability of these interventions in individual cases or series.  
Year introduced: 1992

#### Therapeutic Equivalency

4. The relative equivalency in the **efficacy** of different modes of treatment of a disease, most often used to compare the **efficacy** of different pharmaceuticals to treat a given disease.

Send to:

#### PubMed Search Builder

```
("Alzheimer Disease/drug therapy"  
[Majr]) AND "Treatment Outcome"[Mesh]
```

Add to search builder AND

Search PubMed

YouTube Tutorial

#### Find related data

Database: Select

Find items

#### Search details

efficacy[All Fields]

Search

See more...





["Alzheimer Disease/drug therapy"[Majr]] AND "Treatment Outcome"[Mesh]

Search

Advanced Create alert Create RSS

User Guide

Save

Email

Send to

Sort by:

Most recent


Display options

MY NCBI FILTERS

1,585 results

Page 1 of 159

RESULTS BY YEAR



TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

ARTICLE ATTRIBUTE

- Associated data

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.

Cite Faridar A, Eid AM, Thome AD, Zhao W, Beers DR, Pascual MB, Nakawah MO, Roman GC, Davis CS, Grundman M, Masdeu JC, Appel SH.

Share Transl Neurodegener. 2023 Nov 16;12(1):54. doi: 10.1186/s40035-023-00387-5. PMID: 37968718 [Free PMC article](#). Clinical Trial.

Evaluation of clinical benefits of treatments for Alzheimer's disease.

Cite Liu KY, Walsh S, Brayne C, Merrick R, Richard E, Howard R.

Share Lancet Healthy Longev. 2023 Nov;4(11):e645-e651. doi: 10.1016/S2666-7568(23)00193-9. PMID: 37924845 [Free article](#). Review.

Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.

Cite Alkon DL, Sun MK, Tuchman AJ, Thompson RE.

Share J Alzheimers Dis. 2023;96(2):759-766. doi: 10.3233/JAD-230868.



PubMed Advanced Search Builder



Add terms to the query box

All Fields

ADD

Show Index

Query box

Search

Storico delle  
ricerche  
eseguite

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#1	...	>	Search: ("Alzheimer Disease/drug therapy"[Majr]) AND "Treatment Outcome"[Mesh] Sort by: Most Recent	1,585	04:42:23

Showing 1 to 1 of 1 entries



## Esempio di entry terms nel MeSH

### Entry Terms:

- Alzheimer Syndrome
- Alzheimer-Type Dementia (ATD)
- Alzheimer Type Dementia (ATD)
- Dementia, Alzheimer-Type (ATD)
- Primary Senile Degenerative Dementia
- Dementia, Primary Senile Degenerative
- Alzheimer Type Senile Dementia
- Alzheimer Dementia
- Alzheimer Dementias
- Dementia, Alzheimer
- Alzheimer's Disease
- Dementia, Senile
- Senile Dementia
- Dementia, Alzheimer Type
- Alzheimer Type Dementia
- Senile Dementia, Alzheimer Type
- Alzheimer Sclerosis
- Sclerosis, Alzheimer
- Alzheimer's Diseases
- Alzheimer Diseases
- Alzheimers Diseases
- Acute Confusional Senile Dementia
- Senile Dementia, Acute Confusional

### Recent Activity

[Turn Off](#) [Clear](#)

 Alzheimer Disease MeSH

 alzheimer (36) MeSH

[See more...](#)





See Also:

- [Amyloid beta-Peptides](#)
- [Amyloid beta-Protein Precursor](#)
- [Cerebral Amyloid Angiopathy](#)
- [tau Proteins](#)
- [Neurofilament Proteins](#)
- [Aphasia, Primary Progressive](#)
- [Kluver-Bucy Syndrome](#)

[All MeSH Categories](#)

[Diseases Category](#)

[Nervous System Diseases](#)

[Central Nervous System Diseases](#)

[Brain Diseases](#)

[Dementia](#)

**Alzheimer Disease**

[All MeSH Categories](#)

[Diseases Category](#)

[Nervous System Diseases](#)

[Neurodegenerative Diseases](#)

[Tauopathies](#)

**Alzheimer Disease**

[All MeSH Categories](#)

[Psychiatry and Psychology Category](#)

[Mental Disorders](#)

[Neurocognitive Disorders](#)

[Dementia](#)

**Alzheimer Disease**

Esempio di relazioni  
gerarchiche tra termini  
MeSH con  
struttura ad albero



# Ricerca per autore



Cercare un autore con il cognome e l'iniziale del nome, senza punteggiatura, nella ricerca semplice.

moro s [X] Search [User Guide]


Save Email Send to Sort by: Best match [v] Display options [g]

MY NCBI FILTERS [x]

400 results

<< < Page 1 of 40 > >>

RESULTS BY YEAR



TEXT AVAILABILITY

- Abstract
- Free full text

1 Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. Zusso M, Lunardi V, Franceschini D, Pagetta A, Lo R, Stifani S, Frigo AC, Giusti P, **Moro S.** J Neuroinflammation. 2019 Jul 18;16(1):148. doi: 10.1186/s12974-019-1538-9. PMID: 31319868 Free PMC article. Review.

2 Correction: Bassani, D.; Moro, S. Past, Present, and Future Perspectives on Computer-Aided Drug Design Methodologies. *Molecules* 2023, 28, 3906. Bassani D, **Moro S.** Molecules. 2023 Jul 5;28(13):5223. doi: 10.3390/molecules28135223. PMID: 37446950 Free PMC article.





PubMed®

moro s

Advanced Create alert Create RSS User Guide

Save Email Send to Sort by: Most recent

MY NCBI FILTERS

RESULTS BY YEAR

TEXT AVAILABILITY

Abstract

Free full text

Full text

ARTICLE ATTRIBUTE

Associated data

1  [Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for Recognition of Human Adenosine Receptors.](#)

Cite Salmaso V, Persico M, Da Ros T, Spalluto G, Kachler S, Klotz KN, **Moro S**, Federico S. *Biomolecules*. 2023 Nov 3;13(11):1610. doi: 10.3390/biom13111610.

Share PMID: 38002292 [Free PMC article.](#)

2  [2-Pentadecyl-2-oxazoline inhibits lipopolysaccharide-induced microglia activation interfering with TLR4 signaling.](#)

Cite Facci L, Bolego C, Chemello C, Yasser R, Fusco M, Barbierato M, Giusti P, **Moro S**, Zusso M. *Life Sci*. 2023 Nov 10;122242. doi: 10.1016/j.lfs.2023.122242. Online ahead of print.

Share PMID: 37952834 [Free article.](#)

3  [Perception of the McGurk effect in people with one eye depends on whether the eye is removed during infancy or adulthood.](#)

Cite **Moro SS**, Qureshi FA, Steeves JKE. *Front Neurosci*. 2023 Oct 13;17:1217831. doi: 10.3389/fnins.2023.1217831. eCollection 2023.

Share PMID: 37901426 [Free PMC article.](#)





> Biomolecules. 2023 Nov 3;13(11):1610. doi: 10.3390/biom13111610.

## Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors

Veronica Salmaso<sup>1</sup>, Margherita Persico<sup>2</sup>, Tatiana Da Ros<sup>2</sup>, Giampiero Spalluto<sup>2</sup>, Sonja Kachler<sup>3</sup>, Karl-Norbert Klotz<sup>3</sup>, Stefano Moro<sup>1</sup>, Stephanie Federico<sup>2</sup>

Affiliations + expand

PMID: 38002292 PMID: PMC10669182 DOI: 10.3390/biom13111610

Free PMC article

### FULL TEXT LINKS



### ACTIONS



### SHARE



### PAGE NAVIGATION



moro s  [User Guide](#)

Search results

> Biomolecules. 2023 Nov 3;13(11):1610. doi: 10.3390/biom13111610.

## Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors

Veronica Salmaso<sup>1</sup>, Margherita Persico<sup>2</sup>, Tatiana Da Ros<sup>2</sup>, Giampiero Spalluto<sup>2</sup>, Sonja Kachler<sup>3</sup>, Karl-Norbert Klotz<sup>3</sup>, Stefano Moro<sup>1</sup>, Stephanie Federico<sup>2</sup>

Affiliations

### Affiliations

- 1 Molecular Modeling Section (MMS), Dipartimento di Scienze del Farmaco, Università di Padova, Via Marzolo 5, I-35131 Padova, Italy.
- 2 Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, Via Licio Giorgieri 1, I-34127 Trieste, Italy.
- 3 Institut für Pharmakologie, Universität of Würzburg, Versbacher Str. 9, D-97078 Würzburg, Germany.


PMID: 38002292 PMCID: PMC10669182 DOI: 10.3390/biom13111610

[Free PMC article](#)

FULL TEXT LINKS



ACTIONS



SHARE



PAGE NAVIGATION

< Title & authors

Abstract

Conflict of interest

NEXT RESULT  
2 of 400 >

E' possibile verificare a quali istituzioni afferiscono gli autori





Cercare un autore con il cognome e l'iniziale del nome, senza punteggiatura, nella ricerca advanced selezionando il campo autore.

PubMed Advanced Search Builder



Add terms to the query box

Author

Moro s

ADD

Show Index

Query box


Enter / edit your search query here

Search

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#3	...		Search: <b>Moro S</b> Sort by: <b>Most Recent</b>	400	04:52:06
#2	...	>	Search: <b>moro s</b> Sort by: <b>Most Recent</b>	400	04:47:11
#1	...	>	Search: (" <b>Alzheimer Disease/drug therapy</b> "[Majr]) AND " <b>Treatment Outcome</b> "[Mesh] Sort by: <b>Most Recent</b>	1,585	04:42:23



- Abstract
- Free full text
- Full text

- Associated data

- Books and Documents

Filters applied: Review. [Clear all](#)

**Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.**

1 Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F.  
Cite Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6.  
Share PMID: 33035532 [Free article.](#) [Review.](#)  
**Alzheimer's disease** (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. ...Due to gastrointestinal side effects of these **drugs**, medicinal chemist ...

**High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.**

2 Villain N, Planche V, Levy R.  
Cite Rev Neurol (Paris). 2022 Dec;178(10):1011-1030. doi: 10.1016/j.neurol.2022.06.012. Epub 2022 Sep 29.  
Share PMID: 36184326 [Free article.](#) [Review.](#)  
In 2021, aducanumab, an immunotherapy targeting amyloid-beta, was approved for **Alzheimer's disease** (AD) by the US Food and **Drug** Administration thanks to positive results on a putative biological surrogate marker. ...Here, we review the available eviden ...

E' possibile autenticarsi per salvare i risultati delle ricerche e/o ricevere aggiornamenti, basati su una determinata ricerca.



[User Guide](#)

Add terms to the query box

All Fields

ADD

[Show Index](#)

Query box

Enter / edit your search query here

Search

Storico delle  
ricerche  
eseguite

### History and Search Details

[Download](#) [Delete](#)

Search	Actions	Details	Query	Results	Time
#4	...	>	Search: <b>Moro s[Author]</b> Sort by: <b>Most Recent</b>	400	04:55:29
#3	...		Search: <b>Moro S</b> Sort by: <b>Most Recent</b>	400	04:52:06
#1	...	>	Search: (" <b>Alzheimer Disease/drug therapy</b> "[Majr]) AND " <b>Treatment Outcome</b> "[Mesh] Sort by: <b>Most Recent</b>	1,585	04:42:23

Showing 1 to 3 of 3 entries





(alzheimer drugs AND (2014:2024[pdat])) AND (efficacy)

Search

Advanced Create alert Create RSS

User Guide

Save Email Send to

Sort by: Best match

Display options

### Your saved search

\* Name of saved search: Alzheimer drugs/efficacy

\* Search terms: (alzheimer drugs AND (2014:2024[pdat])) AND

[Test search terms](#)

Would you like email updates of new search results?

Yes

No

Email: [beatrice.stengel@unipd.it](mailto:beatrice.stengel@unipd.it)  
(change)

Salvare i risultati delle ricerche e/o ricevere aggiornamenti, basati su una determinata ricerca.



**Grazie dell'attenzione**  
**Per informazioni, chiarimenti,**  
**assistenza alla ricerca**  
**bibliografica, scrivete a:**  
**[biblio.scienzedelfarmaco@unipd.it](mailto:biblio.scienzedelfarmaco@unipd.it)**